Compare PRSU & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSU | IOVA |
|---|---|---|
| Founded | 1926 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 946.6M | 1.0B |
| IPO Year | N/A | 2008 |
| Metric | PRSU | IOVA |
|---|---|---|
| Price | $35.00 | $3.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $31.67 | $10.08 |
| AVG Volume (30 Days) | 182.9K | ★ 11.1M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.24 | $57.99 |
| Revenue Next Year | $6.25 | $52.63 |
| P/E Ratio | $3.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.90 | $1.64 |
| 52 Week High | $39.93 | $4.57 |
| Indicator | PRSU | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 71.60 |
| Support Level | $34.61 | $1.94 |
| Resistance Level | $37.75 | $3.73 |
| Average True Range (ATR) | 1.24 | 0.23 |
| MACD | -0.14 | 0.13 |
| Stochastic Oscillator | 58.98 | 63.21 |
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.